The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
GridelliC, GalloC, MorabitoA, Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: The G-STEP trial. J Thorac Oncol. 2012;7(1):233–242.
2.
KatakamiN, SugiuraT, NogamiT, Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: A phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer. 2004;43(1):93–100.
3.
SaitoH, NakagawaK, TakedaK, Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004. Am J Clin Oncol. 2012;35(1):58–63.
4.
YamamotoN, NakagawaK, UejimaH, Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer. 2006;107(3):599–605.
5.
GridelliC, CigolariS, GalloC, Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31(2-3):277–284.
6.
GridelliC, GalloC, ShepherdFA, Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol.2003;21(16):3025–3034.
7.
LilenbaumRC, ChenCS, ChidiacT, Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2005;16(1):97–101.
8.
TanEH, SzczesnaA, KrzakowskiM, Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005;49(2):233–240.
9.
GridelliC, FrontiniL, PerroneF, Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses. Gem Vin Investigators. Br J Cancer.2000;83(6):707–714.
10.
EstebanE, VillanuevaN, MunizI, Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: Outcome data on a randomized phase II study. Invest New Drugs. 2008;26(1):67–74.
11.
LaackE, DickgreberN, MullerT, Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: From the German and Swiss Lung Cancer Study Group. J Clin Onco. 2004;22(12):2348–2356.
12.
EstebanE, FraJ, FernandezY, Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study. Invest New Drugs. 2006;24(3):241–248.
13.
BoniC, TiseoM, BoniL, Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: A multicenter randomised factorial trial (FAST). Br J Cancer. 2012;106(4):658–665.
14.
FrasciG, LorussoV, PanzaN, Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18(13):2529–2536.
15.
FrasciG, LorussoV, PanzaN, Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer.2001;34(Suppl 4): S65–69.
16.
GrecoFA, GrayJRJr., ThompsonDS, Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: A Minnie Pearl Cancer Research Network trial. Cancer. 2002;95(6):1279–1285.
17.
GrecoFA, SpigelDR, KuzurME, Paclitaxel/carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: A phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007;8(8):483–487.
18.
ArayaT, KasaharaK, KimuraH, Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: Multicenter phase II trial. Lung Cancer. 2007;56(3):371–376.
19.
HanJY, LeeDH, SongJE, Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Cancer. 2008;113(2):388–395.
20.
ChenYM, PerngRP, ShihJF, TsaiCM, Whang-PengJ.A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated. Lung Cancer. 2005;47(3): 373–380.
21.
ChenYM, PerngRP, YangKY, A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest. 2000;117(6):1583–1589.
22.
FlottenO, GronbergBH, BremnesR, Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012;107(3):442–447.
23.
DonadioM, ArdineM, BerrutiA, Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: A phase II study. Cancer Chemother Pharmacol. 2003;52(2):147–152.
24.
StemmlerHJ, di GioiaD, FreierW, et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br J Cancer. 2011;104(7):1071–1078.
25.
ShehataS, SaadE, GodaY, A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer. Hematol Oncol Stem Cell Ther. 2010;3(1):1–6.
26.
SanalSM, GokmenE, KarabulutB, SezginC.Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J. 2002;8(3):171–176.
27.
LoboF, VirizuelaJA, DortaFJ, Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: Results of a phase II trial. Clin Breast Cancer. 2003;4(1):46–50.
28.
ParkIH, RoJ, LeeKS, KimSN, YunYH, NamBH. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Invest New Drugs. 2010;28(5):659–669.
29.
AmadoriD, CarrascoE, RoeselS, A randomized phase II non-comparative study of pemetrexedcarboplatin and gemcitabinevinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. Int J Oncol. 2013;42(5):1778–1785.
30.
MartinM, RuizA, MunozM, Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8(3):219–225.
31.
NicolaidesC, DimopoulosMA, SamantasE, Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2000;11(7):873–875.
32.
ValenzaR, LeonardiV, GebbiaV, AgostaraB.Gemcitabine and vinorelbine in pretreated advanced breast cancer: A pilot study. Ann Oncol. 2000;11(4):495–496.
33.
HaiderK, KornekGV, KwasnyW, Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat. 1999;55(3):203–211.
34.
StathopoulosGP, RigatosSK, PergantasN, Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol. 2002;20(1):37–41.
35.
PallisAG, BoukovinasI, ArdavanisA, A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol. 2012;23(5):1164–1169.
36.
MorabitoA, FilippelliG, PalmeriS, The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: A phase I-II study. Breast Cancer Res Treat. 2003;78(1):29–36.
37.
SpencerA, ReedK, ArthurC.Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J. 2007;37(11):760–766
38.
SuyaniE, SucakGT, AkiSZ, YeginZA, OzkurtZN, YagciM.Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011;90(6):685–691.
39.
PapageorgiouES, TsirigotisP, DimopoulosM, Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol. 2005;75(2):124–129.
40.
Muller-BeissenhirtzH, KasperC, NuckelH, DuhrsenU.Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol. 2005;84(12):796–801.
41.
HuebnerG, LinkH, KohneCH, Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: A randomised prospective phase II trial. Br J Cancer. 2009;100(1):44–49.
TemperoM, PlunkettW, Ruiz Van HaperenV, et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21(18):3402–3408.
49.
HeskethPJ, KrisMG, GrunbergSM, Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103–109.
CarmichaelJ, KeizerHJ, CupissolD, MilliezJ, ScheidelP, SchindlerAE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998;9(5):381–385.
54.
de WitR, de BoerAC, vd LindenGH, StoterG, SparreboomA, VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85(8):1099–1101.
55.
SmithIE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol. 1993;119(6):350–351.
56.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2(3):177–183.
57.
TerreyJP, AaproMS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996;8:281–288.
58.
SmithTJ, KhatcheressianJ, LymanGH, 2006update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
LarsonDL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49(9):1796–1799.
61.
LarsonDL. What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery. 1985;75(3):397–405.
62.
MullinS, BeckwithMC, TylerLS. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000;35(1):57–74.
63.
MillerAB, HoogstratenB, StaquetM, WinklerA.Reporting results of cancer treatment. Cancer. 1981;47(1):207–214.
64.
DelalogeS, LlombartA, Di PalmaM, Gemcitabine in patients with solid tumors and renal impairment: A pharmacokinetic phase I study. Am J Clin Oncol. 2004;27(3): 289–293.
65.
KintzelPE, DorrRT. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21(1):33–64.
66.
MenefeeM, McDevittPW, Chemotherapy DoseFojo T. Modifications. In: BoyiadzisMM, LebowitzPF, FrameJN, FojoT, eds. Hematology-Oncology Therapy. New York: McGraw-Hill Professional; 2006:569–578.
67.
KingPD, PerryMC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6(2):162–176.
68.
FloydJ, MirzaI, SachsB, PerryMC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33(1):50–67.
